Tracey Walker, Contributing Editor
Rivaroxaban reduced hospitalization by 1 day in pulmonary embolism cases
In the treatment of pulmonary embolism (PE) in North American patients, rivaroxaban (Xarelto) reduced length of hospital stay by 1 full day compared to conventional dual therapy, according to data presented at the American College of Emergency Physicians scientific assembly, October 14-17, in Seattle.
Older adults are more likely to ask for vaccine if they know someone with shingles
Personal knowledge of or experience with shingles may be a major driver in a consumer's decision about whether to receive the shingles vaccine, according to a Merck-sponsored survey.
FDA approves first drug to treat two forms of pulmonary hypertension
Before the approval of riociguat, there was no approved nonsurgical therapy for chronic thromboembolic pulmonary hypertension.
Flu vaccinations cut risk of pneumonia hospitalizations by almost 60%, study finds
Study results were based on laboratory-confirmed hospital cases of pneumonia with and without influenza, in 2,320 children and adults. Many previous studies lacked either laboratory confirmation or vaccine status.
FDA addresses IV nutrition shortage with lipid injectable emulsion approval
Under a priority review to help alleviate a drug shortage, FDA has approved lipid injectable emulsion, USP (Clinolipid, Baxter Healthcare) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are unable to eat or drink.
Chronic opioid use increases after bariatric surgery
Chronic use of opioids among obese patients prior to bariatric surgery continues after bariatric surgery, and the dose. has been shown to be greater postoperatively than preoperatively, according to a recent study in the Journal of the American Medical Association.
FDA approves vortioxetine to treat major depressive disorder
FDA approved vortioxetine (Brintellix, Takeda Pharmaceuticals and Lundbeck) to treat adults with major depressive disorder.
FDA warns of increased death risk with tigecycline use
FDA warned September 27 of an increased risk of death associated with intravenous tigecycline (Tygacil) for FDA-approved and non-approved uses.
Digoxin use linked to higher risk of death for patients with newly diagnosed heart failure
Digoxin, commonly used to treat heart conditions, was associated with a 72% higher rate of death among adults with newly diagnosed heart failure, according to a Kaiser Permanente study in the September issue of Circulation: Cardiovascular Quality and Outcomes.
Dapagliflozin as part of triple therapy works well for T2DM
In adult patients with type 2 diabetes mellitus who are uncontrolled on metformin and sulfonylurea, dapagliflozin can be added to help improve HbA1c and reduce fasting plasma glucose, body weight, and seated systolic blood pressure, according to results from a study presented at the 49th Annual Meeting of the European Association for the Study of Diabetes in Barcelona, Spain, in September.


View Results